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Abstract
Background: Genetic screening in families with high risk to develop colorectal cancer (CRC) prevents incurable
disease and permits personalized therapeutic and follow-up strategies. The advancement of next-generation
sequencing (NGS) technologies has revolutionized the throughput of DNA sequencing.
Methods: A series of 16 probands for either familial adenomatous polyposis (FAP; 8 cases) or hereditary
nonpolyposis colorectal cancer (HNPCC; 8 cases) were investigated for intragenic mutations in five CRC familial
syndromes-associated genes (APC, MUTYH, MLH1, MSH2, MSH6) applying both a custom multigene Ion AmpliSeq
NGS panel and conventional Sanger sequencing.
Results: Fourteen pathogenic variants were detected in 13/16 FAP/HNPCC probands (81.3 %); one FAP proband
presented two co-existing pathogenic variants, one in APC and one in MUTYH. Thirteen of these 14 pathogenic
variants were detected by both NGS and Sanger, while one MSH2 mutation (L280FfsX3) was identified only by
Sanger sequencing. This is due to a limitation of the NGS approach in resolving sequences close or within
homopolymeric stretches of DNA. To evaluate the performance of our NGS custom panel we assessed its capability
to resolve the DNA sequences corresponding to 2225 pathogenic variants reported in the COSMIC database for
APC, MUTYH, MLH1, MSH2, MSH6. Our NGS custom panel resolves the sequences where 2108 (94.7 %) of these
variants occur. The remaining 117 mutations reside inside or in close proximity to homopolymer stretches; of these
27 (1.2 %) are imprecisely identified by the software but can be resolved by visual inspection of the region, while
the remaining 90 variants (4.0 %) are blind spots. In summary, our custom panel would miss 4 % (90/2225) of
pathogenic variants that would need a small set of Sanger sequencing reactions to be solved.
Conclusions: The multiplex NGS approach has the advantage of analyzing multiple genes in multiple samples
simultaneously, requiring only a reduced number of Sanger sequences to resolve homopolymeric DNA regions not
adequately assessed by NGS. The implementation of NGS approaches in routine diagnostics of familial CRC is
cost-effective and significantly reduces diagnostic turnaround times.
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Background
Up to 30 % of colorectal cancers (CRC) have evidence of a
familial component and about 5 % arise within well-
characterized hereditary CRC syndromes [1–3]. The most
frequent inherited CRC syndromes are: i) familial adenoma-
tous polyposis (FAP), due to mutations in the adenomatous
polyposis gene (APC); ii) MUTYH-associated polyposis
(MAP), presenting mutations in the MUTYH gene; iii)
hereditary nonpolyposis colorectal cancer (HNPCC), due to
mutations in a DNA mismatch repair gene, most frequently
MLH1 orMSH2 and rarelyMSH6 or PMS2 [3–6].
The introduction of colorectal cancer screening pro-
grams has significantly decreased the occurrence of ad-
vanced CRC. However, large scale mutational screening in
families with high incidence of cancer has been prevented
by the high costs of Sanger DNA sequencing [7]. The
introduction of next-generation sequencing (NGS)
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technologies has revolutionized the speed and throughput
of DNA sequencing [8, 9], facilitating the genomic dissec-
tion of various types of human cancers, including CRC
[10–12]. The capability of NGS technologies to simultan-
eously sequence multiple samples for multiple genes,
starting from a limited amount of DNA [13–15], holds the
promise to significantly reduce the costs of the analysis as
well as the diagnostic response timing.
The purpose of this study was to compare a multigene
NGS approach vs. Sanger sequencing for detection of




A consecutive series of 16 blood samples obtained from 8
FAP and 8 HNPCC probands (11 females; mean age 42.4
± 20.6 years, median 38.5 years) from the Clinical Surgery
I at the University of Padua were used. All probands had a
clinical history of familial CRC syndrome that had not
been molecularly characterized. Each patient provided
written informed consent for genetic testing.
DNA extraction and quantification
DNA was purified using the QIAamp DNA Blood Mini Kit
(Qiagen), and quantified using NanoDrop (Life Technolo-
gies) and Qubit (Life Technologies) platforms. DNA quality
was further evaluated by PCR analysis using the BIOMED
2 PCR multiplex protocol with PCR products analyzed by
DNA 1000 Assay (Life Technologies) on the Agilent 2100
Bioanalyzer on-chip electrophoresis (Agilent Technologies),
as previously described [16].
Deep Sequencing of Multiplex PCR Amplicons
An Ampliseq multigene custom panel was designed to
explore all exons of APC (n = 16; NM_000038.5),
MUTYH (n = 16; NM_001128425.1), MLH1 (n = 17;
NM_000249.3), MSH2 (n = 16; NM_000251.2), and
MSH6 (n = 10; NM_000179.2) genes. The details of the
target regions as produced by the AmpliSeq designer
v2.2.1 are in Additional file 1: Table S1. Thirty nanograms
of DNA were used for multiplex PCR amplification,
followed by ligation of a specific barcode-sequence to
each sample for identification. Emulsion PCR to con-
struct the libraries of clonal sequences was performed
with the Ion OneTouch™ OT2 System (Life Technologies).
The quality of the obtained libraries was evaluated by the
Agilent 2100 Bioanalyzer on-chip electrophoresis (Agilent
Technologies) as previously described [16]. Sequencing of
the libraries was performed on Personal Genome Machine
(PGM, Life Technologies) using the Ion 318 Chip Kit v2.
Four samples were processed in each emulsion PCR and
sequencing. Data analysis, including alignment to the hg19
human reference genome and variant calling, was done
using the Torrent Suite Software v3.6 (Life Technologies).
Filtered variants were annotated using the SnpEff software
v3.1. Alignments were visually verified with the Integrative
Genomics Viewer (IGV) v2.2 (Broad Institute). Analysis of
blind regions (where automated variant calling is hindered
by sequencing errors due to homopolymers or amplifica-
tion artifacts) was executed as follows: the COSMIC data-
base of SNPs and small INDELs was converted to a
Hotspots file and used to guide variant calling. In this way,
the variant caller is forced to analyze a given hotspot co-
ordinate; if there is no mutation, the software outputs that
the position is “reference”; otherwise it outputs the muta-
tion detected. If there are problems in the sequence at that
position, the software outputs a “no call” value, explaining
why variant calling failed (strand bias, quality of bases,
noise in the sequence, low coverage). All the positions
where a clear variant/reference status could not be called
were further inspected by visual verification of the align-
ment file to ascertain whether the “no call’ status was due
to artifacts or homopolymer misalignment.
DNA Sanger Sequencing
All exons of APC and MUTYH for FAP probands and of
MLH1, MSH2 and MSH6 for HNPCC probands were
analyzed by conventional Sanger sequencing (primer
sequences available upon request). PCR products were
purified using Agencourt AMPure XP magnetic beads
(Beckman Coulter) and labelled with BigDye® Terminator
v3.1 (Applied Biosystems). Agencourt CleanSEQ magnetic
beads (Beckman Coulter) were used for post-labeling
DNA fragment purification, and sequence analysis was




The results of NGS target sequencing are shown in Table 1
and Fig. 1. DNA from all samples was successfully ampli-
fied in multiplex PCR for the 5 considered genes and an
adequate library for NGS was obtained. The mean read
length was 109.5 base pairs and a mean coverage of 1800x
was achieved, with 97 % target bases covered more than
100x, and a minimum coverage of 20x in all cases.
Among the 8 FAP probands, pathogenic mutations in
APC gene were found in 5: three nonsense mutations, one
missense mutation and one splice site alteration. Of inter-
est, the c.3920 T >A (p.I1307K) APC missense alteration
in proband FAP7 was associated with the c.536A >G
(p.Y179C) MAP pathogenic variant in the MUTYH gene
[6, 17, 18]. The splice site alteration is not reported in
either COSMIC (http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic/) or dbSNP (http://www.ncbi.nlm.nih.gov/
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Table 1 Mutations detected at next-generation and Sanger sequencing
Sample APC MUTYH MLH1 MSH2 MSH6
FAP1 c.3433G > T p.E1145*
FAP2
FAP3 c.2805C > A p.Y935*
FAP4 c.834 + 2 T > C
FAP5 c.663A > C p.E221Da
FAP6
FAP7 c.3920 T > A p.I1307K c.536A > G p.Y179C
FAP8 c.694C > T p.R232*
HNPCC1 c.677G > A p.R226Q c.998C > T p.T333Ia
HNPCC2 c.432A > G p.T82A
HNPCC3 c.1731G > A p.S577S
HNPCC4 c.1386 + 1G > T
HNPCC5 c.1216C > T p.R406*
HNPCC6 c.119delG p.G40Afs*24
HNPCC7 c.840_841delAT p.L280Ffs*3 b
HNPCC8 c.1046C > G p.P349R
a variants with uncertain pathogenic potential
b variant detected only by Sanger sequencing
Fig. 1 a Mutations detected at next generation sequencing with the Ion Ampliseq custom panel. b A representative example of Sanger
sequencing validation of a mutation identified using next generation sequencing (sample HNPCC6). On the left is the representation of the
results of next-generation sequencing where the reads are aligned to the reference genome as provided by the Integrative Genomics Viewer
(IGV v.2.1, Broad Institute) software. On the right is the representation of the results of Sanger sequencing
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projects/SNP/) databases. In three FAP probands no
pathogenic mutation was found in APC and MUTYH; one
proband (FAP5) of these three showed the MSH6 variant
c.663A > C (p.E221D; rs41557217), which is described as
HNPCC-related of uncertain pathogenicity in NCBI’s Clin-
Var database (http://www.ncbi.nlm.nih.gov/clinvar/) [19].
Among the 8 HNPCC probands, pathogenic variants
were detected in 7: three in MLH1 and four in MSH2
[20–24]. Of interest, in proband HNPCC1 a MLH1 gene
mutation was associated with the c.998C > T (p.T333I)
variant in the MSH6 gene, which is classified as of
uncertain pathogenicity in NCBI’s ClinVar database [19].
Known non-pathogenic polymorphisms found were as
follows (Fig. 1). The APC c.5465 T > A (p.V1822D) vari-
ant, which has an allelic frequency of 82 % in Caucasian
population [25], in 5 FAP probands (FAP 2,4,5,7,8) and 4
HNPCC probands (HNPCC 1,5,6,8). The MUTYH
c.1014G > C (p.Q338H) [26] in 3 FAP probands (FAP
1,6,8) and 2 HNPCC probands (HNPCC 3,7). The
MLH1 c.655A > G (p.I219V) variant was identified in 5
FAP probands (FAP 1,3,5,6,7) and 2 HNPCC probands
(HNPCC 4,7). All the above variants were also detected
at Sanger sequencing.
Targeted NGS has blind spots
In the present series of 16 probands, all mutations
detected at NGS were also found at Sanger sequencing
(Table 1). However, the HNPCC7 proband c.840_841delAT
(p.L280Ffs*3) mutation in the MSH2 gene was identified
only at Sanger sequencing. This mutation is located in a
region rich of homopolymer stretches, which renders it
both difficult to amplify and prone to artifacts. As a result,
that region had virtually no coverage (i.e. it was covered
around 20x but the base and mapping qualities were not
sufficient for variant calling). A total of 2225 pathogenic
variants are described in the COSMIC database for APC,
MUTYH, MLH1, MSH2, MSH6 (Table 2). Of these
variants, our targeted NGS custom panel shows a clear
sequence of the DNA regions that harbor 2108 (94.7 %) of
these variants, that would then be automatically identified
by the Variant Caller Plugin software (Torrent Suite
Software v3.6; Life Technologies), while the regions harbor-
ing the remaining 117 variants present problems. Twenty-
seven (1.2 %) variants are masked at the software
(Additional file 2: Table S2), i.e. these variants are automat-
ically identified but their proximity to homopolymer
stretches causes imprecise calls that require visual inspec-
tion of the region, using the Integrative Genomics Viewer
(IGV) v2.2 (Broad Institute), to be correctly identified. In
particular, COSMIC variants that are masked and require
visual inspection to be sorted out are 12 for APC; 1 for
MUTYH; 4 for MLH1; 3 for MSH2; 7 for MSH6
(Additional file 2: Table S2). The remaining 90 variants
(4.0 %) are blind spots, i.e. these variants are located at the
end of an amplicon or within homopolymer stretches; in
these cases neither the software nor visual inspection are
able to discern between an artifact and a true alteration. In
particular, the blind spot COSMIC variants are 51 for APC;
10 for MUTYH; 15 for MLH1; 5 for MSH2; 9 for MSH6
(Additional file 2: Table S2).
Targeted NGS blind spots are solved at Sanger
sequencing
The analysis of the entire coding sequence for the APC;
MUTYH; MLH1; MSH2 and MSH6 genes using Sanger se-
quencing requires a number of reactions summing up to 55
for APC, 16 forMUTYH, 39 forMLH1, 30 forMSH2 and 36
forMSH6. Applying our NGS panel the number of Sanger se-
quencing reactions to explore the blind spots would require a
reduced number of reactions: 11 for APC, 2 for MUTYH, 6
forMLH1, 4 forMSH2 and 4 forMSH6 (Table 2).
Cost and time comparison
Cost and time comparison between NGS and Sanger
sequencing are summarized in Table 3. The cost of
consumables for any single PCR product analysis by
Sanger sequencing was €28.0 [27]. For Ion Torrent
sequencing, our initial loading of 4 samples per 318 chip








Solved Solved by IGVb Sensi tivity Blind Spotsc N. Sanger to solve blind spots
APC 8538 1670 55 1607 12 96.9 % 51 11
MUTYH 1854 40 16 29 1 75.0 % 10 2
MHL1 2524 163 39 144 4 90.8 % 15 6
MSH2 11,227 152 30 144 3 96.7 % 5 4
MSH6 4080 200 36 184 7 95.5 % 9 4
Total 28,223 2225 176 2108 27 96.0 % 90 27
a Mutations listed in COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/)
b Integrative Genomics Viewer (IGV v.2.1, Broad Institute) software
c Mutations within homopolymer stretches or artifact-prone regions of the genes
Simbolo et al. Hereditary Cancer in Clinical Practice  (2015) 13:18 Page 4 of 7
was far beyond our theoretical needs, this permitting to
assess the performances of a totally new panel while
being sure to get results even in the worst scenario. In a
routine setup, considering that even a sample (HNPCC6)
producing only 177,000 reads had an average coverage of
670X with all non-blinded regions covered >20X, the
maximum number of samples chargeable on a 318 chip
(max 6,000,000 total reads) for Ion PGM sequencing is 30,
significantly reducing the overall costs to €325.0 per
sample.
Grouping cost analysis for FAP (APC and MUTYH
genes) and HNPCC (MLH1, MSH2 and MSH6 genes)
syndromes, NGS analysis integrated by Sanger sequencing
results significantly cheaper in comparison to Sanger
sequencing alone for both types of probands (Table 3). As
expected, the mean turn-around-time for NGS-based
analysis were significantly lower in comparison to conven-
tional Sanger sequencing.
Discussion
The last few years have been characterized by considerable
consolidation of our genetic understanding of hereditary
CRC syndromes, leading to an increasing request for
genetic testing [28, 29]. However, the costs and time
required for the analysis of multiple genes using Sanger
sequencing is limiting a wider application of genetic
testing. Next-generation sequencing approaches permit
the simultaneous analysis of multiple genes in a limited
period of time. This multigene diagnostic approach has
been already fruitfully applied in oncology [30, 15], and its
introduction in routine practice for the molecular
characterization of probands of colorectal cancer syn-
dromes is foreseen [31].
In this study we compared the gold standard Sanger
sequencing to the Ion Torrent NGS approach for diagnos-
tic application in the screening of familial CRC. A series of
16 probands were investigated for germline intragenic
mutations in five CRC familial syndromes-associated
genes (APC, MUTYH, MLH1, MSH2, MSH6).
The NGS approach used herein and Sanger sequencing
gave overlapping results. Thirteen of 14 pathogenic variants
in the genes tested were detected by both technologies.
Only one MSH2 pathogenic mutation (p.L280Ffs*3)
was identified by Sanger sequencing but not by the NGS.
This is due to a limitation of NGS in resolving sequences
corresponding to DNA homopolymeric stretches. On the
other hand, the multiplex NGS approach has the advantage
residing in the possibility to analyze multiple genes in mul-
tiple samples simultaneously, thus reducing costs and turn-
around time in comparison to Sanger sequencing. With our
custom panel, only three days for library construction and
sequencing of 8 cases was requested; the library production
is quicker as multiplex PCR reactions happen in only one/
two tubes, requiring less DNA and hands-on time even in
absence of automation; the sequencing and analysis proced-
ure may be carried on overnight reducing waiting times;
the visual analysis of NGS tracks is faster and easier than
the verification of electrophoretic peaks on conventional
Sanger sequencing.
To evaluate the performance of our NGS custom
panel we assessed its capability to resolve the DNA se-
quences corresponding to the 2225 pathogenic variants
reported in the COSMIC database for APC, MUTYH,
MLH1, MSH2, MSH6. The analysis using the Torrent
Suite Software clearly resolves the DNA sequences
where 2108 (94.7 %) of these variants occur. The
remaining 117 mutations listed in COSMIC reside in-
side or in close proximity to homopolymer stretches,
and this causes problems in the sequencing reaction of
these areas as well as imprecise calls by the software. Of
these 117 regions, 27 (1.2 %) are automatically identified
by the software but without a clear call, which can be
correctly resolved by the visual inspection of the region;
this visual inspection is however routinely performed
for all called variants and as such already part of analysis
times depicted in Table 3. The remaining 90 variants
(4.0 %) are blind spots, i.e. these variants are located at
the end of an amplicon or within homopolymer
stretches, and in these cases neither the software nor
visual inspection are able to discern between an artifact
and a true alteration. In summary, our custom panel
would miss 4 % (90/2225) of pathogenic variants that
would need a small set of Sanger sequencing reactions
to be solved. Moreover, longer amplicon (375 bp)
designs have been made available, and such constant
improvement in software design, together with the con-
tinuous engineering of reagents (improved sequencing
polymerases have become available) is also expected to
Table 3 Comparison of indicative costs and time per sample
FAP HNPCC
Sanger NGS + Sanger Sanger NGS + Sanger
PCR reactions 71 reactions × 28.0 € = 1988.0 € 13 reactions × 28.0 € = 364.0 € 105 reactions × 28.0 € = 2940.0 € 14 reactions × 28.0 € = 392.0 €
PGMa 0 325.0 € 0 325.0 €
Total costs 1988.0 € 689.0 € 2940.0 € 717.0 €
Indicative timing 25 days 15 days 28 days 16 days
a PGM, Ion Torrent Personal Genome Machine (Life technologies)
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solve most of the blind spots, reducing the need of
complementary Sanger sequencing. Another by-design
limitation of the present AmpliSeq panel is that it can-
not detect large (>100 bp) insertion and deletions, due
to the size (100–200 bp) of the amplicons produced by
multiplex PCR. These large insertions and deletion are
anticipated to be detectable by a copy number variation
approach that is available in the latest version of both
the AmpliSeq designer and analysis software.
An important advantage of NGS resides in the possi-
bility to analyze genes that are usually not assessed due
to adjunctive costs not covered by the National Health
Systems, and this may uncover previously unknown
combined mutations in affected families or individuals.
Probands FAP5 and FAP7 are representative examples of
the benefit of using a multigene mutational analysis. In
FAP7 Sanger sequencing identified only an APC
c.3920 T > A (p.I1307K) mutation, and this would have
probably stopped the analysis for this patient, as it is a
FAP pathogenic mutation, albeit its clinical significance
is still controversial [32, 33]; the NGS multiplex
approach revealed a coexistent MUTYH c.536A > G
(p.Y179C) mutation, which is reported as pathogenic and
related to MAP syndrome [6, 17, 18]. Similarly, in FAP5
the presence of MSH6 c.663A > C (p.E221D) was identi-
fied, this variant has been related to Lynch syndrome
although it is of uncertain clinical significance [19].
Conclusions
Despite the limitation of hard sequencing regions, the
multigene and multi-sample NGS approach showed major
benefits on costs and time required compared to conven-
tional Sanger sequencing. Therefore, NGS technology can
be included as an adequate diagnostic method for the
identification of intragenic mutation testing of familial
CRC syndromes, complemented in the mutation-negative
cases with a reduced number of Sanger sequences to
resolve the DNA regions not adequately assessed by NGS.
Additional files
Additional file 1: Table S1. NGS custom panel targeted regions.
(DOCX 28 kb)
Additional file 2: Table S2. Masked and Blind Spot in Custom Panel.
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